Belharra Therapeutics, Inc.

Based in California, US, and founded in 2021 by Christopher G. Parker, John Teijaro, Benjamin Cravatt, and Stuart Schreiber, Belharra Therapeutics operates as a drug discovery platform that develops novel drugs and therapies for difficult-to-treat diseases. In January 2023, Belharra Therapeutics, Inc. raised USD 130 million in Series A funding from new investors Genentech, Inc.

and Versant Ventures. The firm’s partners include Scripps Research and Genentech. The company operates a chemoproteomic-based drug discovery platform that identifies functional and actionable non-covalent, small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type. The platform allows screens to be run in a whole cell context, allowing the small molecule library to interact with proteins in their native conformations, including protein complexes, to create and identify therapeutics for previously difficult-to-treat conditions.